Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyzine pamoate versus bepotastine besilate as rituximab premedication in non-Hodgkin lymphoma
jRCTs051220169Phase 2Completed
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hydroxyzine, bepotastine, acetaminophen and rituximab in non-Hodgkin lymphoma (NHL) (2 arms). Started May 2023; status: completed.
02
Drugs
hydroxyzinebepotastineacetaminophenrituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCTs051220169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220169.